Veeva Systems (VEEV)
(Delayed Data from NYSE)
$204.67 USD
+0.14 (0.07%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $204.53 -0.14 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$204.67 USD
+0.14 (0.07%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $204.53 -0.14 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Zacks News
Masimo's (MASI) PVi Favored by New Study for Pediatric Patients
by Zacks Equity Research
Masimo's (MASI) PVi is expected to take better treatment decisions for pediatric patients with signs of obstructive respiratory disease in the EDs.
NextGen Healthcare's (NXGN) Solutions Selected by MHHC
by Zacks Equity Research
NextGen Healthcare's (NXGN) solutions get chosen by MHHC that can help serve the latter's rapidly growing community efficiently.
Veeva Systems (VEEV) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal first-quarter results are likely to reflect a solid show by its segments and robust product portfolio.
The Zacks Analyst Blog Highlights 8x8, Duck Creek Technologies, Paycom Software and Veeva Systems
by Zacks Equity Research
8x8, Duck Creek Technologies, Paycom Software and Veeva Systems have been included in this Analyst Blog.
Shockwave Medical's (SWAV) IVL Cleared for Use in China
by Zacks Equity Research
Shockwave Medical's (SWAV) latest regulatory approval is expected to serve a wider patient pool.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from strategic deals. However, intense competition remains a woe.
Baidu (BIDU) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Baidu's (BIDU) first-quarter results are expected to reflect the AI business's strength and gains from expanding autonomous driving efforts.
Dell Technologies (DELL) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Dell Technologies' (DELL) first-quarter fiscal 2023 performance is expected to reflect strong PC sales and solid growth in servers amid supply-chain constraints and higher component costs.
4 Stocks to Buy on Surge in Cloud Infrastructure Spending
by Ritujay Ghosh
A rapid rise in spending on cloud infrastructure services is helping companies like 8x8, Inc. (EGHT), Duck Creek Technologies, Inc. (DCT), Paycom Software, Inc. (PAYC) and Veeva Systems Inc. (VEEV).
VMware (VMW) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
VMware's (VMW) first-quarter fiscal 2023 performance is likely to have benefited from a strong portfolio and an expanding partner base.
BOX Gears Up to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
BOX's first-quarter fiscal 2023 results are likely to reflect gains from the growing adoption of content cloud solutions. Also, growing efforts toward product innovation might have been a tailwind.
What's in the Cards for Agilent Technologies' (A) Q2 Earnings?
by Zacks Equity Research
Agilent Technologies' (A) fiscal second-quarter results are expected to reflect portfolio strength and momentum across all segments.
PerkinElmer (PKI) Boosts Genomic Testing Portfolio With urWGS
by Zacks Equity Research
PerkinElmer's (PKI) urWGS will improve outcomes for critically ill patients in NICUs and PICUs.
Can Veeva (VEEV) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Veeva (VEEV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Hold on to DexCom (DXCM) Stock Now
by Zacks Equity Research
DexCom (DXCM) continues to benefit from a solid product portfolio and a strong international presence. However, supply constraints remain a woe.
BD (BDX) Introduces New Molecular Diagnostic Platform in US
by Zacks Equity Research
BD's (BDX) new fully-automated, high-throughput infectious disease molecular diagnostics platform in the United States to aid lab technicians in prioritizing higher value work.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments.
Here's Why You Should Retain West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
GAN Limited (GAN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
GAN Limited (GAN) delivered earnings and revenue surprises of 10% and 11.23%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
BD (BDX) Extends Partnership to Boost Diagnostic Blood Collection
by Zacks Equity Research
BD (BDX) expands strategic partnership with Babson Diagnostics that will enable less invasive blood sample collection easier and patient-centric.
Here's Why You Should Hold on to Stryker (SYK) Stock for Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure weighs on it.
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vince Surgical System. Higher production costs are a woe.
Ziff Davis (ZD) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Ziff Davis (ZD) delivered earnings and revenue surprises of -5.38% and 2.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
AudioEye (AEYE) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AudioEye (AEYE) delivered earnings and revenue surprises of 25.58% and 1.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
QuinStreet (QNST) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
QuinStreet (QNST) delivered earnings and revenue surprises of -18.18% and 1.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?